Background/Case Studies: There are currently four laboratory-based cellular therapy fellowships in the United States, with Mayo Clinic being the country’s first documented Cellular Therapy Fellowship program dedicated to manufacturing. The Mayo Clinic cellular therapy fellows work within three distinct laboratories, the Human Cellular Therapy Laboratory (HCTL), the Biopharmaceutical Unit (BPU), and the Advanced Biomanufacturing Laboratory at the Center for Regenerative Biotherapeutics (CRB), each with its own unique processing and oversight needs. For cellular therapy fellows, mastering manufacturing and processing demands, while navigating the stringent regulatory and accreditation standards can be challenging, especially given the field’s novelty and the lack of standardized training resources. To address this, we developed a reference guidebook designed to support the laboratory director training of our cellular therapy fellows.
Study
Design/Methods: The guidebook provides information relevant to a laboratory director's role in ensuring the safety, purity, and potency of human cells and tissues regulated under the Public Health Service Act sections 351 and 361. It covers key topics and common challenges such as on call responsibilities, required meetings and conferences, guidance on effective communication between laboratories and across clinical departments, and how to address frequent call-related questions including resolving issues related to cell collection, processing, cryopreservation, administration, donor eligibility, product sterility, out-of-specification or missed doses, and environmental monitoring referencing key SOPs, FACT/AABB standards, and FDA regulations.
Results/Findings: Unlike most residency and fellowship programs which rely on a hierarchical structure with senior trainees onboarding new trainees, cellular therapy fellowship programs typically span one or two years and usually accept only a single fellow at a time. Cellular therapy fellowships can greatly benefit from offering a guidebook as a training resource to enhance competency development by providing clear expectations and responsibilities for fellows, as well as providing resources and troubleshooting guidance for a consistent approach to laboratory director decisions. Conclusions: A robust training program is essential for advancing the development of effective and sustainable cell and gene therapies (CGTs). As the field continues to grow, standardization of education and access to educational toolkits tailored to training the next generation of laboratory directors will be imperative. To support this progress, it is important that training programs share their educational strategies and reference materials provided to fellows, contributing to the overall advancement and consistency of the field.
